Autolus Therapeutics shares promising data on obe-cel treatment for leukemia at 2024 congress
Summary: Autolus Therapeutics presented new clinical data at the 2024 Lymphoma, Leukemia & Myeloma Congress, indicating that their treatment, obe-cel, may be effective without the need for a stem cell transplant in certain patients with relapsed/refractory B-Cell Acute Lymphoblastic Leukemia.
The findings show that patients with lower tumor burden at lymphodepletion had better outcomes when treated solely with obe-cel. This contrasts with previous studies suggesting that stem cell transplants were necessary for improved results in similar patients.
In the study, 78% of patients treated with obe-cel achieved remission. Among those who did not undergo a transplant, 49% remained in remission, compared to 28% of those who did. Further research is needed to confirm these results and optimize treatment strategies.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings